KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Long-Term Debt Repayments (2021 - 2023)

Historic Long-Term Debt Repayments for Halozyme Therapeutics (HALO) over the last 3 years, with Q1 2023 value amounting to $13.5 million.

  • Halozyme Therapeutics' Long-Term Debt Repayments changed N/A to $13.5 million in Q1 2023 from the same period last year, while for Dec 2023 it was $13.5 million, marking a year-over-year change of. This contributed to the annual value of $13.5 million for FY2023, which is 8876.42% down from last year.
  • As of Q1 2023, Halozyme Therapeutics' Long-Term Debt Repayments stood at $13.5 million.
  • Halozyme Therapeutics' Long-Term Debt Repayments' 5-year high stood at $369.1 million during Q4 2021, with a 5-year trough of -$130.0 million in Q4 2022.
  • Over the past 3 years, Halozyme Therapeutics' median Long-Term Debt Repayments value was $131.7 million (recorded in 2022), while the average stood at $125.6 million.
  • The largest annual percentage gain for Halozyme Therapeutics' Long-Term Debt Repayments in the last 5 years was 13522.42% (2022), contrasted with its biggest fall of 13522.42% (2022).
  • Halozyme Therapeutics' Long-Term Debt Repayments (Quarter) stood at $369.1 million in 2021, then plummeted by 135.22% to -$130.0 million in 2022, then surged by 110.37% to $13.5 million in 2023.
  • Its Long-Term Debt Repayments was $13.5 million in Q1 2023, compared to -$130.0 million in Q4 2022 and $250.0 million in Q3 2022.